Mykofenolatmofetil Actavis (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mykofenolatmofetil Actavis, is an immunosuppressant (antimetabolite) presented as an oral formulation for systemic use. It is employed to prevent acute rejection in organ transplantation, to treat lupus nephritis, and to reduce graft‑versus‑host disease in stem‑cell transplant recipients.

GNH USA supplies Mykofenolatmofetil Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mykofenolatmofetil Actavis is used in immunologic conditions where suppression of lymphocyte activity is required.

Kidney transplant: prevents acute graft rejection. Heart transplant: prevents acute graft rejection. Liver transplant: prevents acute graft rejection. Lupus nephritis: reduces renal inflammation and proteinuria. Graft‑versus‑host disease: lowers incidence after allogeneic stem‑cell transplantation.

Mykofenolatmofetil Actavis may cause a range of adverse reactions.

Common Side Effects: - Nausea - Diarrhea - Headache - Abdominal pain - Infections (upper respiratory, urinary) - Anemia

Serious or Rare Side Effects: - Severe infection (including opportunistic pathogens) - Progressive multifocal leukoencephalopathy - Malignancy (e.g., lymphoproliferative disorders) - Bone‑marrow suppression (leukopenia, thrombocytopenia) - Hepatic toxicity (elevated transaminases, hepatitis) - Severe allergic reactions (rash, Stevens‑Johnson syndrome).

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood counts: perform regular CBC to detect cytopenias. Assess renal function: adjust dosing if creatinine clearance is reduced. Evaluate liver enzymes: monitor for hepatotoxicity. Avoid in pregnancy: drug is category D with known teratogenic risk. Counsel on contraception: use effective methods throughout treatment. Store at ambient temperature: keep in the original pack, protect from moisture.

Mykofenolatmofetil Actavis can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Live vaccines: increased risk of infection. - Antacids containing aluminum or magnesium: reduce drug absorption. - Rituximab: heightened infection risk.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels. - CYP3A4 inducers (e.g., rifampin): may lower plasma levels. - NSAIDs: potential for increased nephrotoxicity. - ACE inhibitors or ARBs: additive renal effects, monitor kidney function.